Amy Emerson

Amy Emerson is a clinical researcher specialising in clinical trials of psychedelic‑assisted psychotherapy with a particular focus on MDMA‑assisted interventions for post‑traumatic stress disorder (PTSD). She has served as a co‑investigator and author on multiple phase 2 randomised, double‑blind trials that evaluated dose‑response effects and clinical outcomes in populations such as military veterans, firefighters and police officers, and has contributed to pooled longitudinal analyses of these trials to characterise durability of change.

Her work spans clinical outcome research and translational neuroscience, including studies that examine altered brain activity and functional connectivity following MDMA‑assisted therapy. Emerson has also been involved in pilot research exploring MDMA‑assisted therapy for anxiety and psychological distress related to life‑threatening illness, and in the study design and rationale that informed subsequent phase 3 trials. Across these projects she has contributed to methodological developments in safety assessment, suicidality measurement, and long‑term follow‑up, and to interdisciplinary collaborations that bridge clinical psychiatry, psychotherapy research and neuroimaging.